Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides

Nucleic Acid Therapeutics

Volumn 25, Issue 5, 2015, Pages 275-284

  Burki, Umar ^a   Keane, Jonathan ^a   Blain, Alison ^a   O'Donovan, Liz ^b   Gait, Michael John ^b   Laval, Steven H ^a   Straub, Volker ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MORPHOLINO OLIGONUCLEOTIDE; PEPTIDE; TRYPSIN; ANTISENSE OLIGONUCLEOTIDE; CELL PENETRATING PEPTIDE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; DIAPHRAGM; DNA PROBE; DRUG DETERMINATION; DRUG EXPOSURE; DUCHENNE MUSCULAR DYSTROPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; HEART; IN VIVO STUDY; KIDNEY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER; MAXIMUM PLASMA CONCENTRATION; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CHEMISTRY; SUBCUTANEOUS DRUG ADMINISTRATION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CELL-PENETRATING PEPTIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; INJECTIONS, SUBCUTANEOUS; LIMIT OF DETECTION; MICE, INBRED MDX; MORPHOLINOS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 84941897892     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0528     Document Type: Article

References (38)

1. Siva K, G Covello and MA Denti. (2014). Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Ther 24:69-86.
2. Veltrop M and A Aartsma-Rus. (2014). Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases. Exp Cell Res 325: 50-55.
3. van Deutekom JC, AA Janson, IB Ginjaar, WS Frankhuizen, A Aartsma-Rus, M Bremmer-Bout, JT den Dunnen, K Koop, AJ van der Kooi, et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677-2686.
4. Kinali M, V Arechavala-Gomeza, L Feng, S Cirak, D Hunt, C Adkin, M Guglieri, E Ashton, S Abbs, et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918-928.
5. Cirak S, V Arechavala-Gomeza, M Guglieri, L Feng, S Torelli, K Anthony, S Abbs, ME Garralda, J Bourke, et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
6. Goemans NM, M Tulinius, JT van den Akker, BE Burm, PF Ekhart, N Heuvelmans, T Holling, AA Janson, GJ Platenburg, et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364:1513-1522.
7. Saleh AF, AA Arzumanov and MJ Gait. (2012). Overview of alternative oligonucleotide chemistries for exon skipping. Methods Mol Biol 867:365-378.
8. Amantana A, HM Moulton, ML Cate, MT Reddy, T Whitehead, JN Hassinger, DS Youngblood and PL Iversen. (2007). Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 18:1325-1331.
9. Jearawiriyapaisarn N, HM Moulton, B Buckley, J Roberts, P Sazani, S Fucharoen, PL Iversen and R Kole. (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16:1624-1629.
10. Yin H, HM Moulton, C Betts, Y Seow, J Boutilier, PL Iverson and MJ Wood. (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18:4405-4414.
11. Yin H, HM Moulton, C Betts, T Merritt, Y Seow, S Ashraf, Q Wang, J Boutilier and MJ Wood. (2010). Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther 18:1822-1829.
12. Bigelow JC, LR Chrin, LA Mathews and JJ McCormack. (1990). High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids. J Chromatogr 533:133-140.
13. Leeds JM, MJ Graham, L Truong and LL Cummins. (1996). Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235:36-43.
14. Reyderman L and S Stavchansky. (1996). Determination of single-stranded oligodeoxynucleotides by capillary gel electrophoresis with laser induced fluorescence and on column derivatization. J Chromatogr A 755:271-280.
15. Chen S-H, M Qian, JM Brennan and JM Gallo. (1997). Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis. J Chromatogr B Biomed Sci Appl 692:43-51.
16. Gaus HJ, SR Owens, M Winniman, S Cooper and LL Cummins. (1997). On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 69:313-319.
17. Griffey RH, MJ Greig, HJ Gaus, K Liu, D Monteith, M Winniman and LL Cummins. (1997). Characterization of oligonucleotide metabolism in vivo via liquid chromatography/ electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer. J Mass Spectrom 32:305-313.
18. Wei X, G Dai, G Marcucci, Z Liu, D Hoyt, W Blum and KK Chan. (2006). A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices. Pharm Res 23:1251-1264.
19. Yu RZ, B Baker, A Chappell, RS Geary, E Cheung and AA Levin. (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304:19-25.
20. Verhaart IE, L van Vliet-van den Dool, JA Sipkens, SJ de Kimpe, IG Kolfschoten, JC van Deutekom, L Liefaard, JE Ridings, SR Hood and A Aartsma-Rus. (2014). The dynamics of compound, transcript, and protein effects after treatment with 2OMePS antisense oligonucleotides in mdx mice. Mol Ther Nucleic Acids 3:e148.
21. Heemskerk HA, CL de Winter, SJ de Kimpe, P van Kuik-Romeijn, N Heuvelmans, GJ Platenburg, GJ van Ommen, JC van Deutekom and A Aartsma-Rus. (2009). In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11:257-266.
22. Verhaart IE, CL Tanganyika-de Winter, TG Karnaoukh, IG Kolfschoten, SJ de Kimpe, JC van Deutekom and A Aartsma-Rus. (2013). Dose-dependent pharmacokinetic profiles of 2′-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice. Nucleic Acid Ther 23:228-237.
23. Betts C, AF Saleh, AA Arzumanov, SM Hammond, C Godfrey, T Coursindel, MJ Gait and MJ Wood. (2012). Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol Ther Nucleic Acids 1:e38.
24. Desai NA and V Shankar. (2003). Single-strand-specific nucleases. FEMS Microbiol Rev 26:457-491.
25. Dingwall C, GP Lomonossoff and RA Laskey. (1981). High sequence specificity of micrococcal nuclease. Nucleic Acids Res 9:2659-2673.
26. Horz W and W Altenburger. (1981). Sequence specific cleavage of DNA by micrococcal nuclease. Nucleic Acids Res 9:2643-2658.
27. Schnell FJ, SL Crumley, DV Mourich and PL Iversen. (2013). Development of novel bioanalytical methods to determine the effective concentrations of phosphorodiamidate morpholino oligomers in tissues and cells. Biores Open Access 2:61-66.
28. Arora V, DC Knapp, MT Reddy, DD Weller and PL Iversen. (2002). Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 91:1009-1018.
29. Hudziak RM, E Barofsky, DF Barofsky, DL Weller, SB Huang and DD Weller. (1996). Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 6:267-272.
30. Youngblood DS, SA Hatlevig, JN Hassinger, PL Iversen and HM Moulton. (2007). Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug Chem 18:50-60.
31. Alter J, F Lou, A Rabinowitz, H Yin, J Rosenfeld, SD Wilton, TA Partridge and QL Lu. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175-177.
32. Jarver P, T Coursindel, SE Andaloussi, C Godfrey, MJ Wood and MJ Gait. (2012). Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol Ther Nucleic Acids 1:e27.
33. Laufer SD and T Restle. (2008). Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems. Curr Pharm Des 14:3637-3655.
34. Sazani P, F Gemignani, SH Kang, MA Maier, M Manoharan, M Persmark, D Bortner and R Kole. (2002). Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 20:1228-1233.
35. Du L, R Kayali, C Bertoni, F Fike, H Hu, PL Iversen and RA Gatti. (2011). Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum Mol Genet 20:3151-3160.
36. Pane M, R Scalise, A Berardinelli, G D'Angelo, V Ricotti, P Alfieri, I Moroni, L Hartley, MC Pera, et al. (2013). Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscul Disord 23:451-455.
37. Perronnet C, C Chagneau, P Le Blanc, N Samson-Desvignes, D Mornet, S Laroche, S De La Porte and C Vaillend. (2012). Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice. Hum Mol Genet 21:2263-2276.
38. Goodnough CL, Y Gao, X Li, MQ Qutaish, LH Goodnough, J Molter, D Wilson, CA Flask and X Yu. (2014). Lack of dystrophin results in abnormal cerebral diffusion and perfusion in vivo. Neuroimage 102 (Pt 2):809-816.